DANYELZA
Generic: NAXITAMAB
Basic Information
Manufacturer
Y-mAbs Therapeutics, Inc.
Product Type
HUMAN PRESCRIPTION DRUG
Route of Administration
INTRAVENOUS
FDA Set ID
29a80c6b-8bad-4650-8c7f-f18490c868ec
Indications & Usage
1 INDICATIONS AND USAGE DANYELZA is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), for the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy.
This indication is approved under accelerated approval based on overall response rate and duration of response [see Clinical Studies (14) ] .
Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
DANYELZA is a GD2-binding monoclonal antibody indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), for the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy.
This indication is approved under accelerated approval based on overall response rate and duration of response.
Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
( 1 )
This indication is approved under accelerated approval based on overall response rate and duration of response [see Clinical Studies (14) ] .
Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
DANYELZA is a GD2-binding monoclonal antibody indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), for the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy.
This indication is approved under accelerated approval based on overall response rate and duration of response.
Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
( 1 )
Adverse Reactions
6 ADVERSE REACTIONS The following clinically significant adverse reactions are also described elsewhere in the labeling: Serious Infusion-Related Reactions [see Warnings and Precautions (5.1) ] Neurotoxicity [see Warnings and Precautions (5.2) ] Myocarditis [see Warnings and Precautions (5.3) ] Hypertension [see Warnings and Precautions (5.4) ] Orthostatic Hypotension [see Warnings and Precautions (5.5) ] The most common adverse reactions (≥25%) are infusion-related reaction, pain, tachycardia, vomiting, cough, nausea, diarrhea, decreased appetite, hypertension, fatigue, erythema multiforme, peripheral neuropathy, urticaria, pyrexia, headache, injection site reaction, edema, anxiety, localized edema, and irritability ( 6.1 ).
The most common Grade 3 or 4 laboratory abnormalities (≥5%) are decreased lymphocytes, decreased neutrophils, decreased hemoglobin, decreased platelet count, decreased potassium, increased alanine aminotransferase, decreased glucose, decreased calcium, decreased albumin, decreased sodium, and decreased phosphate ( 6.1 ).
To report SUSPECTED ADVERSE REACTIONS, contact Y-mAbs Therapeutics, Inc, at 1-833-339-6227 (1-833-33YMABS), or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety of DANYELZA in combination with GM-CSF was evaluated in patients with refractory or relapsed high-risk neuroblastoma in bone or bone marrow who had demonstrated a partial response, minor response, or stable disease following initial or subsequent therapy, and in patients who were in second complete remission, from two open-label, single arm studies, Study 201 (n=25) and Study 12-230 (n=72).
Patients received DANYELZA 9 mg/kg/cycle administered as three separate intravenous infusions of 3 mg/kg (Day 1, 3 and 5) in the first week of each cycle.
Patients also received GM-CSF 250 µg/m 2 /day subcutaneously on Days -4 to 0 and GM-CSF 500 µg/m 2 /day subcutaneously on Days 1 to 5 [see Clinical Studies (14) ].
The most common adverse reactions in Studies 201 and 12-230 (≥25% in either study) were infusion-related reaction, pain, tachycardia, vomiting, cough, nausea, diarrhea, decreased appetite, hypertension, fatigue, erythema multiforme, peripheral neuropathy, urticaria, pyrexia, headache, injection site reaction, edema, anxiety, localized edema and irritability.
The most common Grade 3 or 4 laboratory abnormalities (≥5% in either study) were decreased lymphocytes, decreased neutrophils, decreased hemoglobin, decreased platelet count, decreased potassium, increased alanine aminotransferase, decreased glucose, decreased calcium, decreased albumin, decreased sodium and decreased phosphate.
Study 201 In Study 201, among 25 patients who received DANYELZA in combination with GM-CSF, 12% were exposed for 6 months or longer and none were exposed for greater than one year.
Serious adverse reactions occurred in 32% of patients who received DANYELZA in combination with GM-CSF.
Serious adverse reactions in more than one patient included anaphylactic reaction (12%) and pain (8%).
Permanent discontinuation of DANYELZA due to an adverse reaction occurred in 12% of patients.
Adverse reactions resulting in permanent discontinuation of DANYELZA included anaphylactic reaction (8%) and respiratory depression (4%).
Dosage interruptions of DANYELZA due to an adverse reaction occurred in 84% of patients.
Adverse reactions requiring dosage interruption in > 10% of patients included hypotension and bronchospasm.
Table 4 summarizes adverse reactions in Study 201.
Table 4.
Adverse Reactions (>10%) in Patients with Refractory or Relapsed High-Risk Neuroblastoma in Bone or Bone Marrow Who Received DANYELZA with GM-CSF in Study 201 DANYELZA with GM-CSF Adverse reactions were graded using CTCAE version 4.0.
(n=25) Adverse Reaction All Grades (%) Grade 3 or 4 (%) Body system General disorders and administration site conditions Pain Pain includes pain, abdominal pain, pain in extremity, bone pain, neck pain, back pain, and musculoskeletal pain.
100 72 Infusion-related reaction Infusion-related reaction includes hypotension, bronchospasm, flushing, wheezing, stridor, urticaria, dyspnea, pyrexia, infusion-related reaction, face edema, edema mouth, tongue edema, lip edema, respiratory tract edema, chills, hypoxia, pruritis and rash occurring on the day of infusion or the day following an infusion.
100 68 Edema 28 0 Fatigue Fatigue includes fatigue, asthenia.
28 0 Pyrexia Pyrexia not occurring on the day of infusion or the day following an infusion 28 0 Respiratory, thoracic and mediastinal disorders Cough 60 0 Rhinorrhea 24 0 Vascular disorders Hypertension 44 4 Gastrointestinal disorders Vomiting 60 4 Diarrhea 56 8 Nausea 56 0 Skin and subcutaneous tissue disorders Urticaria Urticaria, not occurring on the day of infusion or the day following an infusion 32 4 Cardiac disorders Tachycardia Tachycardia includes sinus tachycardia and tachycardia 84 4 Nervous system disorders Peripheral neuropathy Peripheral neuropathy includes peripheral sensory neuropathy, paresthesia, neuralgia.
32 0 Headache 28 8 Depressed level of consciousness 24 16 Eye disorders Neurological disorders of the eye Neurological disorders of the eye includes unequal pupils, blurred vision, and mydriasis.
24 0 Immune system disorders Anaphylactic reaction 12 12 Metabolism and nutrition disorders Decreased appetite 16 0 Infections and infestations Influenza 12 0 Rhinovirus infection 12 0 Upper respiratory tract infection 12 0 Investigations Weight decreased 12 0 Psychiatric disorders Anxiety 12 0 Clinically relevant adverse reactions occurring in ≤10% of patients who received DANYELZA with GM-CSF included peripheral edema (8%).
Table 5 summarizes the laboratory abnormalities in Study 201.
Table 5.
Selected Laboratory Abnormalities (>20%) Worsening from Baseline in Patients with Refractory or Relapsed High-Risk Neuroblastoma in Bone or Bone Marrow Who Received DANYELZA with GM-CSF in Study 201 Laboratory Abnormality DANYELZA with GM-CSF The table presents laboratory parameters with available grading according to CTCAE version 4.0.
Baseline evaluation was the last non-missing value prior to first DANYELZA dosing.
Each test incidence is based on the number of patients who had both a baseline value and at least one on-study laboratory measurement (range: 23 to 24 patients).
n=25 All Grades (%) Grade 3 or 4 (%) Chemistry Decreased potassium 63 8 Decreased albumin 50 0 Increased alanine aminotransferase 42 8 Decreased sodium 29 0 Hematology Decreased lymphocytes 74 30 Decreased platelet count 65 17 Decreased neutrophils 61 39 Decreased hemoglobin 48 4 Study 12-230 In Study 12-230, among 72 patients who received DANYELZA in combination with GM-CSF, 32% were exposed for 6 months or longer and 8% were exposed for greater than one year.
Serious adverse reactions occurred in 40% of patients who received DANYELZA in combination with GM-CSF.
Serious adverse reactions in > 5% of patients included hypertension (14%), hypotension (11%), and pyrexia (8%).
Permanent discontinuation of DANYELZA due to an adverse reaction occurred in 8% of patients.
Four (6%) patients permanently discontinued DANYELZA due to hypertension and one (1.4%) patient discontinued due to RPLS.
Table 6 summarizes adverse reactions in Study 12-230.
Table 6.
Adverse Reactions (>10%) in Patients with Refractory or Relapsed High-Risk Neuroblastoma in Bone or Bone Marrow Who Received DANYELZA with GM-CSF in Study 12-230 DANYELZA with GM-CSF In Study 12-230, all adverse reactions occurring in Cycle 1 and 2, and adverse reactions of ≥ Grade 3 severity occurring in subsequent cycles were reported.
In the dose finding phase, Grade 2 unexpected adverse reactions were also reported for Cycles 3 and later.
, Adverse reactions were graded using CTCAE version 4.0.
(n=72) Adverse Reaction All Grades (%) Grade 3 or 4 (%) Body system General disorders and administration site conditions Infusion-related reaction Infusion-related reaction includes hypotension, bronchospasm, flushing, wheezing, stridor, urticaria, dyspnea, pyrexia, face edema, periorbital edema, lip swelling, swollen tongue, chills, hypoxia, pruritis, rash maculopapular and rash erythematous occurring on the day of infusion or the day following an infusion.
94 32 Pain Pain includes pain, abdominal pain, pain in extremity, bone pain, neck pain, back pain, non-cardiac chest pain, flank pain, and musculoskeletal pain.
94 2.8 Fatigue Fatigue includes fatigue, asthenia.
44 0 Injection site reaction 28 0 Localized edema 25 0 Pyrexia Pyrexia not occurring on the day of infusion or the day following an infusion.
11 0 Vascular disorders Hypertension 28 7 Gastrointestinal disorders Vomiting 63 2.8 Nausea 57 1.4 Diarrhea 50 4.2 Constipation 15 0 Skin and subcutaneous tissue disorders Erythema multiforme 33 0 Hyperhidrosis 17 0 Erythema 11 0 Respiratory, thoracic and mediastinal disorders Cough 57 0 Oropharyngeal pain 15 0 Rhinorrhea 15 0 Nervous system disorders Peripheral neuropathy Peripheral neuropathy includes peripheral sensory neuropathy, peripheral motor neuropathy, paresthesia, neuralgia.
25 0 Headache 18 0 Lethargy 14 0 Metabolism and nutrition disorders Decreased appetite 53 4.2 Cardiac disorders Sinus tachycardia 44 1.4 Psychiatric disorders Anxiety 26 0 Irritability 25 0 Investigations Breath sounds abnormal 15 0 Injury and procedural complications Contusion 15 0 Infections and infestations Rhinovirus infection 14 0 Enterovirus infection 13 0 Eye Disorders Neurological disorders of the eye Neurological disorders of the eye includes unequal pupils, blurred vision, accommodation disorder, visual impairment and photophobia.
19 0 Clinically relevant adverse reactions in ≤10% of patients who received DANYELZA with GM-CSF included apnea (4.2%), hypopnea (2.8%), generalized edema (2.8%), peripheral edema (8.3%), and device related infection (4.2%).
Table 7 summarizes the laboratory abnormalities in Study 12-230.
Table 7.
Selected Laboratory Abnormalities (>20%) Worsening from Baseline in Patients with Refractory or Relapsed High-Risk Neuroblastoma in Bone or Bone Marrow Who Received DANYELZA with GM-CSF in Study 12-230 Laboratory Abnormality DANYELZA with GM-CSF The table presents laboratory parameters with available grading according to CTCAE version 4.0.
Baseline evaluation was the last non-missing value prior to first DANYELZA dosing.
Each test incidence is based on the number of patients who had both a baseline value and at least one on-study laboratory measurement (range 19 to 72 patients).
n=72 All Grades (%) Grade 3 or 4 (%) Chemistry Increased glucose 74 0 Decreased albumin 68 7 Decreased calcium 64 8 Increased alanine aminotransferase 55 9 Decreased magnesium 54 0 Increased aspartate aminotransferase 49 4 Decreased phosphate 47 5 Decreased potassium 47 32 Decreased sodium 38 6 Decreased glucose 29 8 Hematology Decreased lymphocytes 79 56 Decreased hemoglobin 76 42 Decreased neutrophils 72 46 Decreased platelets 71 40 6.2 Immunogenicity As with all therapeutic proteins, there is a potential for immunogenicity.
The detection of anti-drug antibody formation is highly dependent on the sensitivity and specificity of the assay.
Additionally, the observed incidence of anti-drug antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors, including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease.
For these reasons, comparison of the incidence of anti-drug antibodies in the studies described below with the incidence of anti-drug antibodies in other studies or to other naxitamab products may be misleading.
In Study 201, 2 of 24 (8%) patients tested positive for anti-drug antibodies (ADA) after treatment with DANYELZA.
In Study 12-230, 27 of 117 patients (23%) tested positive for ADA after treatment with DANYELZA by an assay that was not fully validated; therefore, the incidence of ADA may not be reliable.
6.3 Postmarketing Experience/Spontaneous Reports The following adverse reactions have been identified during expanded access and post-approval use of DANYELZA.
Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Neurological: Orthostatic hypotension, Transverse myelitis Cardiac disorders: Myocarditis
The most common Grade 3 or 4 laboratory abnormalities (≥5%) are decreased lymphocytes, decreased neutrophils, decreased hemoglobin, decreased platelet count, decreased potassium, increased alanine aminotransferase, decreased glucose, decreased calcium, decreased albumin, decreased sodium, and decreased phosphate ( 6.1 ).
To report SUSPECTED ADVERSE REACTIONS, contact Y-mAbs Therapeutics, Inc, at 1-833-339-6227 (1-833-33YMABS), or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety of DANYELZA in combination with GM-CSF was evaluated in patients with refractory or relapsed high-risk neuroblastoma in bone or bone marrow who had demonstrated a partial response, minor response, or stable disease following initial or subsequent therapy, and in patients who were in second complete remission, from two open-label, single arm studies, Study 201 (n=25) and Study 12-230 (n=72).
Patients received DANYELZA 9 mg/kg/cycle administered as three separate intravenous infusions of 3 mg/kg (Day 1, 3 and 5) in the first week of each cycle.
Patients also received GM-CSF 250 µg/m 2 /day subcutaneously on Days -4 to 0 and GM-CSF 500 µg/m 2 /day subcutaneously on Days 1 to 5 [see Clinical Studies (14) ].
The most common adverse reactions in Studies 201 and 12-230 (≥25% in either study) were infusion-related reaction, pain, tachycardia, vomiting, cough, nausea, diarrhea, decreased appetite, hypertension, fatigue, erythema multiforme, peripheral neuropathy, urticaria, pyrexia, headache, injection site reaction, edema, anxiety, localized edema and irritability.
The most common Grade 3 or 4 laboratory abnormalities (≥5% in either study) were decreased lymphocytes, decreased neutrophils, decreased hemoglobin, decreased platelet count, decreased potassium, increased alanine aminotransferase, decreased glucose, decreased calcium, decreased albumin, decreased sodium and decreased phosphate.
Study 201 In Study 201, among 25 patients who received DANYELZA in combination with GM-CSF, 12% were exposed for 6 months or longer and none were exposed for greater than one year.
Serious adverse reactions occurred in 32% of patients who received DANYELZA in combination with GM-CSF.
Serious adverse reactions in more than one patient included anaphylactic reaction (12%) and pain (8%).
Permanent discontinuation of DANYELZA due to an adverse reaction occurred in 12% of patients.
Adverse reactions resulting in permanent discontinuation of DANYELZA included anaphylactic reaction (8%) and respiratory depression (4%).
Dosage interruptions of DANYELZA due to an adverse reaction occurred in 84% of patients.
Adverse reactions requiring dosage interruption in > 10% of patients included hypotension and bronchospasm.
Table 4 summarizes adverse reactions in Study 201.
Table 4.
Adverse Reactions (>10%) in Patients with Refractory or Relapsed High-Risk Neuroblastoma in Bone or Bone Marrow Who Received DANYELZA with GM-CSF in Study 201 DANYELZA with GM-CSF Adverse reactions were graded using CTCAE version 4.0.
(n=25) Adverse Reaction All Grades (%) Grade 3 or 4 (%) Body system General disorders and administration site conditions Pain Pain includes pain, abdominal pain, pain in extremity, bone pain, neck pain, back pain, and musculoskeletal pain.
100 72 Infusion-related reaction Infusion-related reaction includes hypotension, bronchospasm, flushing, wheezing, stridor, urticaria, dyspnea, pyrexia, infusion-related reaction, face edema, edema mouth, tongue edema, lip edema, respiratory tract edema, chills, hypoxia, pruritis and rash occurring on the day of infusion or the day following an infusion.
100 68 Edema 28 0 Fatigue Fatigue includes fatigue, asthenia.
28 0 Pyrexia Pyrexia not occurring on the day of infusion or the day following an infusion 28 0 Respiratory, thoracic and mediastinal disorders Cough 60 0 Rhinorrhea 24 0 Vascular disorders Hypertension 44 4 Gastrointestinal disorders Vomiting 60 4 Diarrhea 56 8 Nausea 56 0 Skin and subcutaneous tissue disorders Urticaria Urticaria, not occurring on the day of infusion or the day following an infusion 32 4 Cardiac disorders Tachycardia Tachycardia includes sinus tachycardia and tachycardia 84 4 Nervous system disorders Peripheral neuropathy Peripheral neuropathy includes peripheral sensory neuropathy, paresthesia, neuralgia.
32 0 Headache 28 8 Depressed level of consciousness 24 16 Eye disorders Neurological disorders of the eye Neurological disorders of the eye includes unequal pupils, blurred vision, and mydriasis.
24 0 Immune system disorders Anaphylactic reaction 12 12 Metabolism and nutrition disorders Decreased appetite 16 0 Infections and infestations Influenza 12 0 Rhinovirus infection 12 0 Upper respiratory tract infection 12 0 Investigations Weight decreased 12 0 Psychiatric disorders Anxiety 12 0 Clinically relevant adverse reactions occurring in ≤10% of patients who received DANYELZA with GM-CSF included peripheral edema (8%).
Table 5 summarizes the laboratory abnormalities in Study 201.
Table 5.
Selected Laboratory Abnormalities (>20%) Worsening from Baseline in Patients with Refractory or Relapsed High-Risk Neuroblastoma in Bone or Bone Marrow Who Received DANYELZA with GM-CSF in Study 201 Laboratory Abnormality DANYELZA with GM-CSF The table presents laboratory parameters with available grading according to CTCAE version 4.0.
Baseline evaluation was the last non-missing value prior to first DANYELZA dosing.
Each test incidence is based on the number of patients who had both a baseline value and at least one on-study laboratory measurement (range: 23 to 24 patients).
n=25 All Grades (%) Grade 3 or 4 (%) Chemistry Decreased potassium 63 8 Decreased albumin 50 0 Increased alanine aminotransferase 42 8 Decreased sodium 29 0 Hematology Decreased lymphocytes 74 30 Decreased platelet count 65 17 Decreased neutrophils 61 39 Decreased hemoglobin 48 4 Study 12-230 In Study 12-230, among 72 patients who received DANYELZA in combination with GM-CSF, 32% were exposed for 6 months or longer and 8% were exposed for greater than one year.
Serious adverse reactions occurred in 40% of patients who received DANYELZA in combination with GM-CSF.
Serious adverse reactions in > 5% of patients included hypertension (14%), hypotension (11%), and pyrexia (8%).
Permanent discontinuation of DANYELZA due to an adverse reaction occurred in 8% of patients.
Four (6%) patients permanently discontinued DANYELZA due to hypertension and one (1.4%) patient discontinued due to RPLS.
Table 6 summarizes adverse reactions in Study 12-230.
Table 6.
Adverse Reactions (>10%) in Patients with Refractory or Relapsed High-Risk Neuroblastoma in Bone or Bone Marrow Who Received DANYELZA with GM-CSF in Study 12-230 DANYELZA with GM-CSF In Study 12-230, all adverse reactions occurring in Cycle 1 and 2, and adverse reactions of ≥ Grade 3 severity occurring in subsequent cycles were reported.
In the dose finding phase, Grade 2 unexpected adverse reactions were also reported for Cycles 3 and later.
, Adverse reactions were graded using CTCAE version 4.0.
(n=72) Adverse Reaction All Grades (%) Grade 3 or 4 (%) Body system General disorders and administration site conditions Infusion-related reaction Infusion-related reaction includes hypotension, bronchospasm, flushing, wheezing, stridor, urticaria, dyspnea, pyrexia, face edema, periorbital edema, lip swelling, swollen tongue, chills, hypoxia, pruritis, rash maculopapular and rash erythematous occurring on the day of infusion or the day following an infusion.
94 32 Pain Pain includes pain, abdominal pain, pain in extremity, bone pain, neck pain, back pain, non-cardiac chest pain, flank pain, and musculoskeletal pain.
94 2.8 Fatigue Fatigue includes fatigue, asthenia.
44 0 Injection site reaction 28 0 Localized edema 25 0 Pyrexia Pyrexia not occurring on the day of infusion or the day following an infusion.
11 0 Vascular disorders Hypertension 28 7 Gastrointestinal disorders Vomiting 63 2.8 Nausea 57 1.4 Diarrhea 50 4.2 Constipation 15 0 Skin and subcutaneous tissue disorders Erythema multiforme 33 0 Hyperhidrosis 17 0 Erythema 11 0 Respiratory, thoracic and mediastinal disorders Cough 57 0 Oropharyngeal pain 15 0 Rhinorrhea 15 0 Nervous system disorders Peripheral neuropathy Peripheral neuropathy includes peripheral sensory neuropathy, peripheral motor neuropathy, paresthesia, neuralgia.
25 0 Headache 18 0 Lethargy 14 0 Metabolism and nutrition disorders Decreased appetite 53 4.2 Cardiac disorders Sinus tachycardia 44 1.4 Psychiatric disorders Anxiety 26 0 Irritability 25 0 Investigations Breath sounds abnormal 15 0 Injury and procedural complications Contusion 15 0 Infections and infestations Rhinovirus infection 14 0 Enterovirus infection 13 0 Eye Disorders Neurological disorders of the eye Neurological disorders of the eye includes unequal pupils, blurred vision, accommodation disorder, visual impairment and photophobia.
19 0 Clinically relevant adverse reactions in ≤10% of patients who received DANYELZA with GM-CSF included apnea (4.2%), hypopnea (2.8%), generalized edema (2.8%), peripheral edema (8.3%), and device related infection (4.2%).
Table 7 summarizes the laboratory abnormalities in Study 12-230.
Table 7.
Selected Laboratory Abnormalities (>20%) Worsening from Baseline in Patients with Refractory or Relapsed High-Risk Neuroblastoma in Bone or Bone Marrow Who Received DANYELZA with GM-CSF in Study 12-230 Laboratory Abnormality DANYELZA with GM-CSF The table presents laboratory parameters with available grading according to CTCAE version 4.0.
Baseline evaluation was the last non-missing value prior to first DANYELZA dosing.
Each test incidence is based on the number of patients who had both a baseline value and at least one on-study laboratory measurement (range 19 to 72 patients).
n=72 All Grades (%) Grade 3 or 4 (%) Chemistry Increased glucose 74 0 Decreased albumin 68 7 Decreased calcium 64 8 Increased alanine aminotransferase 55 9 Decreased magnesium 54 0 Increased aspartate aminotransferase 49 4 Decreased phosphate 47 5 Decreased potassium 47 32 Decreased sodium 38 6 Decreased glucose 29 8 Hematology Decreased lymphocytes 79 56 Decreased hemoglobin 76 42 Decreased neutrophils 72 46 Decreased platelets 71 40 6.2 Immunogenicity As with all therapeutic proteins, there is a potential for immunogenicity.
The detection of anti-drug antibody formation is highly dependent on the sensitivity and specificity of the assay.
Additionally, the observed incidence of anti-drug antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors, including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease.
For these reasons, comparison of the incidence of anti-drug antibodies in the studies described below with the incidence of anti-drug antibodies in other studies or to other naxitamab products may be misleading.
In Study 201, 2 of 24 (8%) patients tested positive for anti-drug antibodies (ADA) after treatment with DANYELZA.
In Study 12-230, 27 of 117 patients (23%) tested positive for ADA after treatment with DANYELZA by an assay that was not fully validated; therefore, the incidence of ADA may not be reliable.
6.3 Postmarketing Experience/Spontaneous Reports The following adverse reactions have been identified during expanded access and post-approval use of DANYELZA.
Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Neurological: Orthostatic hypotension, Transverse myelitis Cardiac disorders: Myocarditis